About 100 reports

Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc., Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc., Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent,...

  • Biopharmaceutical
  • Biosimilar
  • World
  • United States
  • Biosimilar Approvals
  • Chronic Disease Prevalence

Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc. The global trastuzumab biosimilars market is expected to grow from $2.08 billion in 2021 to $2.64 billion in...

  • Monoclonal Antibody
  • Biosimilar
  • World
  • India

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi. The global pegfilgrastim biosimilars market is expected to grow from $1.17 billion in 2021 to $1.28 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The growth is mainly...

  • Biopharmaceutical
  • Monoclonal Antibody
  • Biosimilar
  • World
  • United States
  • Middle East
  • India
  • APAC
  • Biosimilar Penetration Rate
  • Drug Approval

Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. The global biosimilar lymphocyte modulator market is expected to grow from $1.16 billion in 2021 to $1.34 billion in 2022 at a compound annual growth rate (CAGR) of 15.4%. The growth is mainly due to the companies resuming...

  • Immunotherapy
  • Biosimilar
  • World
  • United States
  • Middle East
  • APAC

Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.93 billion in 2021 to $1.21...

  • Pharmaceutical
  • Biosimilar
  • Chronic Disease
  • Drug Development
  • Biotechnology
  • Therapy
  • World
  • United Kingdom
  • United States
  • Drug Approval
  • Biosimilar Sales

Forecasts by Type of Manufacturing (In-House, CMOs), by Type (Monoclonal Antibodies, Fusion Proteins, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Interferon, Growth Hormones, Fertility Hormones, Others), by Application (Blood Disorders, Oncology Diseases, Chronic & Autoimmune Diseases, Growth Hormone Deficiencies,...

  • Biosimilar
  • Research And Development
  • World
  • Europe
  • Pharmaceutical Production

The biosimilar market in Europe reached a value of US$ 6,735 Million in 2021. Looking forward, the analyst expects the market to reach US$ 25,446 Million by 2027, exhibiting a CAGR of 22.8% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well...

  • Biopharmaceutical
  • Biosimilar
  • Europe
  • Biosimilar Approvals

The biosimilar market reached a value of US$ 13.0 Billion in 2021. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Chronic Disease Prevalence
  • Biosimilar Penetration Rate

Biosimilar Lymphocyte Modulator market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Biosimilar Lymphocyte Modulator Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Biosimilar Lymphocyte Modulator types,...

  • Immunotherapy
  • Biosimilar
  • World

Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, and Mylan. The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in...

  • Monoclonal Antibody
  • Biosimilar
  • World
  • United States

“US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026” Report Highlights: • US Diabetic Drug Market Opportunity: > US$ 35 Billion • US Insulin Market Opportunity > US$ 10 Billion • US Biosimilar Insulin Market Opportunity > US$ 1 Billion • US Biosimilar Insulin Market Cost Comparison Analysis •...

  • Biosimilar
  • United States

“Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026” Report highlights: • Europe Biosimilars Market Opportunity: > USD 10 Billion • Dosage & Pricing insight On Approved Biosimilars • Biosimilars for Cancers Accounts for > 20% Market • Biosimilars for Diabetes Accounts for > 5% Market •...

  • Biopharmaceutical
  • Biosimilar
  • Europe
  • Biosimilar Approvals
  • Health Expenditure

Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd., and EirGenix, Inc. The global trastuzumab biosimilars market is expected to grow from $1.22 billion in 2020 to $1.4 billion in...

  • Monoclonal Antibody
  • Breast Cancer
  • Biosimilar
  • World
  • India
  • China
  • APAC

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi. The global pegfilgrastim biosimilars market is expected to grow from $0.8 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly...

  • Biopharmaceutical
  • Biosimilar
  • Monoclonal Antibody
  • World
  • APAC
  • United Kingdom
  • Biosimilar Penetration Rate
  • Drug Approval

Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion. The global biosimilar lymphocyte modulator market is expected to grow from $1.22 billion in 2020 to $1.31 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The growth is mainly due to the companies resuming...

  • Immunotherapy
  • Biosimilar
  • World
  • United States
  • APAC

Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87...

  • Biosimilar
  • Chronic Disease
  • Drug Development
  • Biotechnology
  • Therapy
  • World
  • United Kingdom
  • United States
  • Drug Approval
  • Biosimilar Sales

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma. The global filgrastim biosimilars market is expected to grow from $0.75...

  • Biosimilar
  • Biopharmaceutical
  • World
  • United States
  • Middle East
  • India
  • APAC
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

Report Scope Biosimilar drugs have gained immense popularity because of their impact on the lives of many patients.These drugs belong to several drug classes including hormones, interferons, growth factors (colony stimulating factors, erythropoietin) and monoclonal antibodies, among others. The use of these drugs...

  • Biosimilar
  • Clinical Trial
  • World
  • United States
  • Biosimilar Penetration Rate

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, and Aryogen Biopharma. The global filgrastim biosimilars market is expected to grow from $0.72...

  • Biosimilar
  • World
  • United States
  • Japan
  • APAC
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Biosimilar Approvals
  • Chronic Disease Prevalence

Global Biosimilar Monoclonal Antibodies (mAbs) Market 2021-2025 The analyst has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by $ 3.48 bn during 2021-2025, progressing at a CAGR of 14.05% during the forecast period. Our report on the biosimilar monoclonal antibodies (mAbs)...

  • Monoclonal Antibody
  • Biosimilar
  • World
  • Chronic Disease Prevalence

"US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026" Report highlights: • US Cancer Biosimilar Market Opportunity: > US$ 15 Billion By 2026 • Currently 29 Cancer Biosimilar Approved In US Market • Pricing & Dosage Insight On More Than 10 Cancer Biosimilar Commercially Available...

  • Biosimilar
  • Therapy
  • United States
  • Mortality Rate
  • Biosimilar Approvals

Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi. The global pegfilgrastim biosimilar market is expected to decline from $534.43 million in 2019 to $453.11 million in 2020 at a compound annual growth rate (CAGR) of -15.22%. The decline...

  • Biopharmaceutical
  • Monoclonal Antibody
  • Biosimilar
  • World
  • Spain
  • United Kingdom
  • Drug Approval

Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG and Novo Nordisk A/S. The global biosimilar therapeutic peptides market is expected to decline from $0.80 billion in 2019 to $0.77...

  • Biosimilar
  • Chronic Disease
  • Drug Development
  • Biotechnology
  • Therapy
  • World
  • United Kingdom
  • Drug Approval
  • Biosimilar Sales

Biosimilar Growth Hormones Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar growth hormones market. This report focuses on biosimilar growth hormones market which is experiencing strong growth. The...

  • Biosimilar
  • World

In this research service, the Transformational Health team provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in...

  • Biopharmaceutical
  • Biosimilar
  • World
  • Biosimilar Penetration Rate
  • Biologics Patents Registrations

"Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" Report Highlights: • Bevacizumab Market Opportunity: > USD 12 Billion by 2025 • Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars • Bevacizumab Biosimilar Available in Market: >8 Biosimilars • Bevacizumab...

  • Biosimilar
  • Cancer
  • Monoclonal Antibody
  • World

Major players in the filgrastim biosimilars market are Cadila Pharmaceuticals, Dr. Reddy’s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon and Aryogen Biopharma. The global filgrastim biosimilars market is expected to decline from $511.15...

  • Biosimilar
  • World
  • United States
  • Biosimilar Approvals
  • Biosimilar Penetration Rate

Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab,...

  • Biopharmaceutical
  • Monoclonal Antibody
  • Biosimilar
  • World
  • APAC

The Global Filgrastim Market size is expected to reach $953.4 million by 2027, rising at a market growth of 8.0% CAGR during the forecast period. Filgrastim refers to the recombinant DNA-derived granulocyte colony-stimulating factor (G-CSF), which is generally utilized to cure low blood neutrophils. It is especially used in cases wherein...

  • Biopharmaceutical
  • Colony Stimulating Factor
  • Biosimilar
  • World
  • United States
  • Tobacco Consumption
  • Drug Approval